Holen Sie sich die Stockscreener-App
3.02
3.07%
0.09
Handel nachbörslich:
3.00
-0.02
-0.66%
Schlusskurs vom Vortag:
$2.93
Offen:
$3
24-Stunden-Volumen:
4.56M
Relative Volume:
3.52
Marktkapitalisierung:
$489.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-274.18M
KGV:
-1.1915
EPS:
-2.5346
Netto-Cashflow:
$-198.33M
1W Leistung:
+14.83%
1M Leistung:
+65.93%
6M Leistung:
+287.28%
1J Leistung:
-73.62%
1-Tages-Spanne:
$2.82
$3.25
1-Wochen-Bereich:
$2.40
$3.25
52-Wochen-Spanne:
$0.611
$14.09
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Vergleichen Sie NMRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
3.02 | 474.50M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-09-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-07 | Herabstufung | Stifel | Buy → Hold |
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
What risks investors should watch in Neumora Therapeutics Inc. stockQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
Will Neumora Therapeutics’ (NMRA) Novel Drug Pipeline Define Its Competitive Edge in Biotech? - simplywall.st
What momentum shifts mean for Neumora Therapeutics Inc.July 2025 WrapUp & Expert Curated Trade Setup Alerts - newser.com
Is Neumora Therapeutics Inc. stock entering bullish territory2025 Market Sentiment & Reliable Price Action Trade Plans - newser.com
Regression analysis insights on Neumora Therapeutics Inc. performance2025 Year in Review & Daily Profit Maximizing Tips - newser.com
Heatmap analysis for Neumora Therapeutics Inc. and competitors2025 Dividend Review & Free High Accuracy Swing Entry Alerts - newser.com
Why Neumora Therapeutics Inc. stock is a must watch in 2025July 2025 WrapUp & Low Volatility Stock Suggestions - newser.com
Neumora Therapeutics Inc. stock outlook for YEARJuly 2025 Review & Free Safe Capital Growth Stock Tips - newser.com
Published on: 2025-10-31 04:44:03 - newser.com
Published on: 2025-10-31 03:53:08 - newser.com
How moving averages guide Neumora Therapeutics Inc. trading2025 Sector Review & Low Risk High Win Rate Picks - newser.com
Neumora Therapeutics (NMRA): Evaluating Valuation Following Dual Pipeline Advances in Psychiatry and Obesity - Yahoo Finance
Can a trend reversal in Neumora Therapeutics Inc. lead to recoveryExit Point & AI Driven Price Predictions - newser.com
Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating - Insider Monkey
Arch Venture Partners Xii, Llc Acquires 1,915,700 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Director Kristina Burow Acquires 1,915,700 Shares - MarketBeat
Is Neumora Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 News Drivers & AI Powered Market Entry Ideas - newser.com
Neumora Therapeutics Stock (NMRA) Opinions on Obesity Drug Data Release - Quiver Quantitative
Guggenheim upgrades Neumora Therapeutics, Inc. (NMRA) to a Buy - The Globe and Mail
Neumora to initiate phase 1 study of oral obesity pill - MSN
Published on: 2025-10-30 01:21:45 - newser.com
Major Stakeholders Make Bold Moves in Neumora Therapeutics! - TipRanks
Neumora Therapeutics (NASDAQ:NMRA) Price Target Raised to $8.00 - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Is Neumora Therapeutics Inc. stock a top pick in earnings season2025 Buyback Activity & Safe Entry Zone Tips - Fundação Cultural do Pará
14 Stocks Under $5 with Highest Upside Potential - Insider Monkey
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $5 to $18 - 富途牛牛
Needham Maintains Neumora Therapeutics (NMRA) Buy Recommendation - Nasdaq
Why hedge funds are buying Neumora Therapeutics Inc. stock2025 Market Trends & Weekly Top Gainers Alerts - Fundação Cultural do Pará
Real time social sentiment graph for Neumora Therapeutics Inc.2025 Top Gainers & Verified Entry Point Signals - newser.com
Published on: 2025-10-30 01:45:00 - newser.com
Will Neumora Therapeutics Inc. stock reach Wall Street targetsEarnings Recap Summary & Weekly Hot Stock Watchlists - Fundação Cultural do Pará
Neumora initiates phase 1 study of second M4 PAM compound By Investing.com - Investing.com Philippines
How Neumora Therapeutics Inc. stock valuations compare to rivalsPortfolio Return Report & Free Safe Entry Trade Signal Reports - Fundação Cultural do Pará
Neumora’s obesity drug shows up to 26% weight loss in preclinical studies - Investing.com Canada
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Breakthrough for Major Depressive Disorder - TipRanks
Neumora Therapeutics’ NMRA-323511 Study: A Potential Breakthrough in Alzheimer’s Treatment - TipRanks
Neumora initiates phase 1 study of second M4 PAM compound - Investing.com
How Neumora Therapeutics Inc. stock performs after earnings2025 Key Highlights & Free Community Consensus Stock Picks - Fundação Cultural do Pará
Is Neumora Therapeutics Inc. stock positioned well for digital economyJuly 2025 Movers & Low Risk High Reward Trade Ideas - Fundação Cultural do Pará
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):